Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia (Globe Newswire)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that it received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for SGT-212, the Company’s investigational gene therapy for Friedreich’s ataxia (FA).
As Holiday Shopping Season Nears, UF Experts Warn Retail Theft Is Growing More Sophisticated (UF News)
UF Innovate | Accelerate client Loss Prevention Research Council and its affiliated UF researchers offer evidence-based insights as retailers report rising crime and growing safety concerns.
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PR Newswire)
UF startup Dialectic Therapeutics has begun patient dosing in a clinical trial of its novel therapy for platinum-resistant ovarian cancer, marking a key milestone in its progress toward new treatment options.
Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (Globe Newswire)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.
NeXtGen Biologics and Lovell Government Services Partner To Bring Innovative Advanced Wound Care Technology to Federal Healthcare Systems (Globe Newswire)
UF Innovate | Accelerate resident client NeXtGen™ Biologics has partnered with Lovell® Government Services to expand access to its advanced wound care technologies across federal healthcare systems, including the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS).
NeXtGen Biologics Successfully Completes First FDA Audit With Zero 483 Observations (Globe Newswire)
UF Innovate | Accelerate resident client NeXtGen Biologics announced the successful completion of a two-day inspection by the U.S. Food and Drug Administration (FDA).
iOncologi Secures Foundational U.S. Patent As Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival With Cancer Immunotherapy (Bio Space))
UF startup iOncologi, Inc. announced that USPTO has granted a U.S. patent for a novel method using RNA-based formulations to enhance tumor responsiveness to immune checkpoint inhibitor (ICI) therapy.
NeXtGen Biologics Announces Issuance of a Third New Patent Covering Axolotl-Derived Technology (Globe Newswire)
UF Innovate | Accelerate resident client NeXtGen Biologics has announced the issuance of its third U.S. patent, part of a broader portfolio of U.S. and international patents focused on extracellular matrix components derived from a highly regenerative, non-mammalian species known as the axolotl, a type of urodele amphibian.
Oragenics Announces Strategic Partnership With Receptor.AI To Accelerate Pipeline Development (Oragenics)
UF Innovate | Accelerate graduate Oragenics announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the potential development of an expanded pharmaceutical-candidate portfolio for potential conditions affecting brain health.
Tech Tuesday: University of Florida Lab Diagnoses and Removes Viruses Through Genome Editing (WCJB TV20)
In this week’s Tech Tuesday, UF Innovate highlights CasNx, a company that uses CRISPR-based technologies for diagnostics and to genome-edit donor organs before transplant.